DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
DALS was delisted on the 28th of July, 2023.
43 hedge funds and large institutions have $151M invested in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 5 closing their positions.
0% more capital invested
Capital invested by funds: $150M → $151M (+$749K)
4% less funds holding
Funds holding: 45 → 43 (-2)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$3.66M |
| 2 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$2.96M |
| 3 |
CF
Cantor Fitzgerald
New York
|
+$1.11M |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$1.05M |
| 5 |
HCM
Highbridge Capital Management
New York
|
+$884K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$4.84M |
| 2 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
-$1.52M |
| 3 |
CL
CSS LLC
Chicago,
Illinois
|
-$1.45M |
| 4 |
Millennium Management
New York
|
-$739K |
| 5 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$553K |
DALS Hedge Fund Activity: Q3 2022 in Review
43 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) for Q3 2022, worth a combined $151M — up 0.5% from $150M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of DALS and 4 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 5 added.
The largest buyer was Mangrove Partners, adding an estimated $3.66M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $4.84M sold.
- 43 institutional investors held DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) as of Q3 2022, down from 45 in Q2 2022.
- Funds reported $151M of DA32 Life Science Tech Acquisition Corp. Class A Common Stock stock for Q3 2022, up 0.5% quarter-over-quarter.
- 4 funds opened new DA32 Life Science Tech Acquisition Corp. Class A Common Stock positions in Q3 2022 and 5 closed out, a net change of -1 holder.
- The largest DA32 Life Science Tech Acquisition Corp. Class A Common Stock buyer in Q3 2022 was Mangrove Partners, an estimated $3.66M added.
- The largest DA32 Life Science Tech Acquisition Corp. Class A Common Stock seller in Q3 2022 was Alyeska Investment Group, an estimated $4.84M sold.
Based on aggregated 13F filings for Q3 2022.